Kither Biotech Initiates Dosing of Patients in Phase 1b / 2a Study of KIT2014 in COPD
- KIT2014 is a novel inhaled peptide therapy being developed for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB), idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF)
- The first patients have now been dosed in Kither’s randomised, double-blind, placebo-controlled, dose-ranging Phase 1b / 2a trial in adults with moderate to severe COPD
- The Australia-based multicentre study will evaluate the safety, tolerability and pharmacokinetics of KIT2014, plus early signs of efficacy
- KIT2014’s unique and proprietary mode of action, involving balanced dual PDE3/4 inhibition, acts to improve respiratory symptoms by enhancing bronchodilation and reducing lung inflammation
Turin, Italy – 29 September 2026 – Kither Biotech Pty Ltd and Kither Biotech Srl, a clinical-stage biopharmaceutical group of companies developing innovative therapies for respiratory diseases, today announced that it has dosed the first patients in its Phase 1b / 2a clinical study of KIT2014 in adults with moderate to severe COPD.
